I doubt people will quibble over a few dollars when their lives may very well be at stake in a couple of years time as these viruses continue to mutate and resistance in other drugs rises.
I even think the company should keep a small stockpile on hand reserved for shareholder emergency access if a global epidemic emerges.
has daiichi sankyo miss priced inavir , page-10
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)